Market News & Trends
Rafael Pharmaceuticals Announces Expansion Into France of Pivotal Phase 3 Trial
Rafael Pharmaceuticals, Inc. recently announced the expansion of its Phase 3 clinical trial for patients with metastatic pancreatic cancer (AVENGER 500) into France. AVENGER 500…
Bellerophon Receives Orphan Drug Designation
Bellerophon Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation to nitric oxide for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF…
Wave Life Sciences Announces Fast Track Designation from US FDA
Wave Life Sciences Ltd. recently announced the US FDA has granted Fast Track designation to suvodirsen for the treatment of Duchenne muscular dystrophy (DMD) in…
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 Trial
Ovid Therapeutics Inc. recently announced the first patient has been randomized in the company’s single, pivotal Phase 3 NEPTUNE clinical trial evaluating OV101 (gaboxadol), a…
Cellectar Presents Data From Phase 1 Study
Cellectar Biosciences, Inc. recently announced Mr. Jarrod Longcor, chief business officer of Cellectar presented data from Cohort 6 of its Phase 1 dose escalation study…
Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial
Allena Pharmaceuticals, Inc. recently announced it has completed enrollment in its pivotal Phase 3 URIROX-1 clinical trial. URIROX-1 is a multi-center, global, randomized, double-blind, placebo-controlled…
Oramed Announces Last Patient Treated in Pivotal Oral Insulin Trial
Oramed Pharmaceuticals Inc. recently announced the treatment of the last patient in the primary cohort of the Phase 2b HbA1c trial evaluating Oramed's lead oral…
TYME Presents Positive Circulating Tumor Cell Data
Tyme Technologies, Inc. recently reported encouraging data on circulating tumor cells (CTCs) and a correlation with decrease in risk of death using TYME's lead candidate,…
Kitov Pharma Presents Newly Released Data for Reversing Pancreatic Cancer Drug Resistance
Kitov Pharma Ltd. recently presented newly released proof-of-concept data showing evidence of NT-219 mechanism of action in reversing cancer drug resistance in PDX models. The…
Toronto Innovation Acceleration Partners Announces Strategic Partnership With Amgen
Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise in the early stage health science field,…